The United Kingdom's dysphagia management business revenue is expected to increase from USD 232.4 million in 2023 to USD 293.3 million by 2033. Over the forecast period, demand for dysphagia management products across the United Kingdom is predicted to rise at a CAGR of 2.4%. Total revenue from the dysphagia management business in the United Kingdom totaled USD 228.2 million at the end of 2022.
The rising prevalence of neurological disorders, structural abnormalities, or other medical conditions is expected to push the cases of dysphagia worldwide. The growing need for treating this condition is expected to drive the demand for dysphagia management solutions.
Key companies are focusing on developing new drugs and medical devices for the management of swallowing disorders in the United Kingdom. This is expected to foster growth in the United Kingdom’s dysphagia management business.
Other Factors Driving Dysphagia Management Demand in the United Kingdom-
| Attributes | Key Insights |
|---|---|
| Dysphagia Management Business Size in the United Kingdom (2022) | USD 228.2 million |
| Estimated United Kingdom Dysphagia Management Business Revenue (2023) | USD 232.4 million |
| Projected United Kingdom Dysphagia Management Business Revenue (2033) | USD 293.3 million |
| Value-based CAGR (2023 to 2033) | 2.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The United Kingdom dysphagia management business recorded a CAGR of 1.2% from 2018 to 2022. Total revenue in the country reached USD 228.2 million at the end of 2022. Over the assessment period, dysphagia management demand in the United Kingdom is predicted to increase at a 2.4% CAGR.
| Historical CAGR (2018 to 2022) | 1.2% |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.4% |
Several factors are expected to spur growth in the United Kingdom's dysphagia management business. These include the rising prevalence of dysphagia and other swallowing disorders, growing health awareness, and increasing spending on swallowing disorder treatment in the United Kingdom.
Dysphagia is especially prevalent among the geriatric population. For instance, studies suggest that dysphagia is thought to affect around 4 million people in the United Kingdom. This will continue to drive demand for dysphagia management solutions.
Certain chronic health conditions, such as gastroesophageal reflux disease (GERD), muscular dystrophy, and scleroderma, can result in dysphagia. Hence, the increasing prevalence of these conditions is expected to create lucrative opportunities for dysphagia management companies.
In the United Kingdom, the National Health Service (NHS) and the Department of Health and Social Care are playing a key role in tackling the burden of swallowing disorders, including dysphagia. This will positively impact overall dysphagia management product sales.
For instance, the Speech and Language Therapy service at Sheffield Teaching Hospital’s NHS Foundation Trust launched a novel bite-sized online learning resource to improve the understanding of dysphagia. These initiatives are likely to boost dysphagia management solution sales.
Dysphagia can lead to feelings of frustration, embarrassment, and isolation. Difficulty in eating and drinking can result in a reduced quality of life, impacting an individual's social interactions and overall happiness. Hence, the importance of dysphagia management is proliferating.
Dysphagia is commonly seen in patients with neurological disorders and stroke. The main symptoms of dysphagia in neurological disorders are delayed oral transit and difficulties in bolus formation, among others. To treat this condition, patients are expected to opt for dysphagia management solutions, including PPIs, feeding devices, and nutritional supplements.
To avoid difficulties in swallowing solid foods, consumers are showing interest in dysphagia supplement products such as powder thickeners and gel thickeners. The increasing adoption of these supplements will boost the total dysphagia management business revenue.
Greater awareness about dysphagia means that healthcare professionals are more likely to identify and diagnose swallowing disorders at an early stage. This can lead to quicker interventions and better outcomes for individuals with dysphagia.
The recognition of dysphagia as a significant health concern can drive research and innovation in the field. This can lead to the development of new diagnostic tools, therapies, and products designed to improve the quality of life for individuals with dysphagia.
The increasing awareness of dysphagia in the United Kingdom and emerging countries is a positive development that can lead to better healthcare outcomes and increased access to dysphagia management services. It will also create new opportunities for innovation and collaboration in the field of dysphagia management.
Principal Consultant
The usage of equipment in high-risk anatomical regions, including the anterior neck, requires specific clearance from the Food & Drug Administration (FDA). The general clearance for neuromuscular stimulation/reeducation is not sufficient. This is acting as an impediment for companies.
Contrary to other body parts, the FDA has always issued a warning label for the use of neuromuscular electrical stimulation (NMES) on the anterior neck. This is because there is a chance of severe harm or death while utilizing general clearance NMES devices and supplies on the neck. This factor is limiting the growth of the target business to a certain extent.
Long-term use of dysphagia drugs such as proton pump inhibitors is associated with certain threats, such as the increased risk of hip bone fracture. This is due to the decreased absorption of calcium and iron and the risk of opportunistic infections with S. pneumonia and C. defficile owing to diminished natural gut flora.
The use of nasogastric tubes or PEG tubes can cause irritation to the throat, which leads to severe discomfort. Long-term administration of such tubes can cause abdominal cramping, abdominal swelling, diarrhea, nausea, vomiting, and regurgitation of food and medicines.
Dysphagia drugs, such as proton pump inhibitors (PPIs) and H2 blockers, are expected to be commonly used to treat GERD, a condition that can cause dysphagia. While these drugs are generally safe and effective, they can cause side effects such as headache, diarrhea, and abdominal pain.
In a handful of cases, long-term use of PPIs has been linked to an increased risk of certain health conditions, such as bone fractures, kidney disease, and other infections. Hence, the side effects of PPIs and feeding tubes can limit their usage, thereby hampering the expansion of the target business.
Growth Outlook by Key States
| States | Value CAGR |
|---|---|
| Greater London | 1.9% |
| West Midlands | 2.8% |
| Greater Manchester | 3.6% |
| West Yorkshire | 5.7% |
| Glasgow | 2.6% |
As per the latest report, Greater London is projected to remain a lucrative pocket for dysphagia management companies across England. Over the forecast period, the demand for dysphagia management solutions in Greater London is projected to rise at a 1.9% CAGR.
By 2033, Greater London’s dysphagia management business revenue is anticipated to reach USD 46.8 million. It will likely hold a share of 21.1% in England by the end of 2033. This is attributable to the rising incidence of dysphagia.
Dysphagia often results from underlying medical conditions such as stroke, Parkinson's disease, and dementia. Greater London's diverse and growing population can experience a higher prevalence of these conditions, driving the demand for dysphagia management.
Awareness among healthcare professionals and the public regarding the diagnosis and management of dysphagia is also growing rapidly in Greater London. This can lead to early diagnosis and intervention, increasing the need for related services.
West Midlands is projected to experience a CAGR of 2.8% during the forecast period. Total dysphagia management sales in the West Midlands are set to reach USD 23.0 million by 2033. The presence of rehabilitation centers and long-term care facilities in the region can drive the demand for dysphagia management products and services, as these institutions often cater to patients with swallowing difficulties.
The presence of well-established healthcare infrastructure, including hospitals, clinics, and skilled healthcare professionals specializing in dysphagia management, can encourage patients to seek treatment across the region. This will boost overall revenue in the West Midlands through 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below shows the drugs segment witnessing a higher CAGR of 5.2% during the assessment period. Based on indication, the oropharyngeal dysphagia category is expected to hold a prominent value share by 2033, exhibiting a CAGR of 1.5%. By distribution channel, the hospital pharmacies segment will retain its dominance in the United Kingdom, thriving at a 1.2% CAGR through 2033.
Growth Outlook by Key Product
| Product | Value CAGR |
|---|---|
| Drugs (Proton Pump Inhibitors) | 5.2% |
| Feeding Tubes | 1.6% |
| Nutritional Solutions | 2.2% |
| Devices | 4.1% |
Based on product, the drugs (proton pump inhibitors) segment is expected to thrive at a 5.2% CAGR during the forecast period. As a result, dysphagia management companies looking to boost their revenue will likely shift their focus on offering novel and effective proton pump inhibitors.
Proton pump inhibitors (PPIs) are primarily prescribed to reduce stomach acid production. By managing conditions such as GERD and acid reflux, which are common causes of dysphagia, PPIs help alleviate the symptoms and underlying causes of swallowing difficulties. This, in turn, leads to better dysphagia management.
PPIs can also help reduce the discomfort associated with acid-related conditions, making it easier for individuals with dysphagia to eat and swallow. This improved comfort can lead to better patient compliance with dysphagia management plans.
Growth Outlook by Indication
| Indication | Value CAGR |
|---|---|
| Oropharyngeal Dysphagia | 1.5% |
| Esophageal Dysphagia | 5.2% |
As per the latest dysphagia management industry analysis, the oropharyngeal dysphagia segment is set to create lucrative revenue generation for dysphagia management companies. This is attributed to the rising prevalence of oropharyngeal dysphagia in the United Kingdom.
The oropharyngeal dysphagia segment is anticipated to expand at a 1.5% CAGR during the forecast period. It is expected to total USD 218.2 million by 2033, accounting for a value share of 74.4% in the United Kingdom.
Oropharyngeal dysphagia patients frequently require speech therapy and rehabilitation to improve their swallowing function. This drives the demand for speech therapists, drugs, medical devices, and rehabilitation facilities, which are key components of the dysphagia management business.
Oropharyngeal dysphagia treatment plans are often tailored to the individual's specific needs and the underlying causes of the condition. This personalization of care can result in a variety of management options and interventions, including dietary modifications and exercises, all of which contribute to revenue growth.
Growth Outlook by Key End-user
| Application | Value CAGR |
|---|---|
| Hospital Pharmacies | 1.2% |
| Retail Pharmacies | 1.8% |
| Drug Stores | 2.9% |
| Specialty Clinics | 5.1% |
Based on end-users, the hospital pharmacies segment is projected to expand at a 1.2% CAGR during the assessment period. As per the latest analysis of dysphagia management in the United Kingdom, the target segment will likely hold a share of about 36.2% by 2033.
Hospital pharmacies are responsible for dispensing medications to patients within the hospital. For dysphagia patients, this can include specialized oral medications or alternative routes of administration, such as enteral feeding through feeding tubes. The availability and proper management of these medications are essential for effective dysphagia treatment.
Strategic partnerships are a priority for leading dysphagia management companies in the United Kingdom as they work to create new product lines and expand their global consumer base. Key players are also investing heavily in research and development to develop cutting-edge dysphagia management tools in the United Kingdom.
Recent Developments in the United Kingdom Dysphagia Management Business
| Attribute | Details |
|---|---|
| Estimated Value (2023) | USD 232.4 million |
| Expected Value (2033) | USD 293.3 million |
| Anticipated Growth Rate (2023 to 2033) | 2.4% CAGR |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | USD million for Value |
| Key Regions Covered | England; Wales; Scotland; Northern Ireland |
| Key States Covered | Greater London, West Midlands, Greater Manchester, West Yorkshire, Rest of England, Cardiff, Swansea, Rhondda Cynon Taf, Carmarthenshire, Rest of Wales, Glasgow, Edinburgh, Aberdeen, Lanarkshire, Rest of Scotland, Antrim, Armagh, Down, Fermanagh, Rest of Northern Ireland |
| Key Segments Covered | Product, Indication, Distribution Channel, and Region |
| Key Companies Profiled | Abbott; Nestlé Health Science; Danone S.A; Hormel Foods Corporation; Fresenius Kabi AG; Cipla Ltd; Eisai Co Ltd; Becton, Dickinson and Company (BD); Cook Medical Inc.; AstraZeneca Plc.; VitalStim UK; Nutricia Limited; Simply Food Solutions Limited; Ampcare, LLC; E2 Scientific Corp; TheraSIP LLC; Phagenesis; ProvaMed®; Kent Precision Foods Group |
| Report Coverage | Future Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
Total revenue is set to reach USD 232.4 million in 2023.
The target business is expected to be valued at USD 293.3 million by 2033.
The drug segment is expected to witness a high CAGR of 5.2% through 2033.
Demand in the United Kingdom is set to rise at a 2.4% CAGR through 2033.
The target business exhibited a 1.2% CAGR from 2018 to 2022.
England will likely hold about 75.7% value share in the United Kingdom in 2033.
Dysphagia affects around 4 million people in the United Kingdom.
Speech-language pathologists, otolaryngologists, gastroenterologists, and neurologists.
Speech and language therapist, physiotherapist, occupational therapist, dietician, and nursing staff.
1. Executive Summary
2. Business Overview
3. Key Trends
4. Value Added Insights
5. Background
6. Demand (in Volume) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7. Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
8. Pricing Analysis
9. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
9.1. Drugs (Proton Pump Inhibitors)
9.2. Feeding Tubes
9.2.1. Naso-gastric Tubes
9.2.2. PEG Tubes
9.3. Nutritional Solutions
9.3.1. Thickeners
9.3.2. Beverages
9.3.3. Purees
9.4. Devices
9.4.1. Medical Cups
9.4.2. Neuromuscular Electrical Stimulation (NEMS)
9.4.3. Tactile-thermal Stimulation (TTS)
9.4.4. Pharyngeal Electrical Stimulation (PES)
10. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
10.1. Oropharyngeal Dysphagia
10.2. Esophageal Dysphagia
11. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Hospital Pharmacies
11.2. Retail Pharmacies
11.3. Drug Stores
11.4. Specialty Clinics
12. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. England
12.2. Wales
12.3. Scotland
12.4. Northern Ireland
13. England Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
14. Wales Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
15. Scotland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
16. Northern Ireland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033
17. Structure Analysis
18. Competition Analysis
18.1. Abbott
18.2. Kent Precision Foods Group
18.3. Nestlé Health Science
18.4. Danone S.A
18.5. Hormel Foods Corporation
18.6. Fresenius Kabi AG
18.7. Cipla Ltd
18.8. Eisai Co Ltd
18.9. Becton, Dickinson and Company (BD)
18.10. Cook Medical Inc.
18.11. AstraZeneca Plc.
18.12. VitalStim UK
18.13. Nutricia Limited
18.14. Simply Food Solutions Limited
18.15. Ampcare, LLC
18.16. E2 Scientific Corp
18.17. TheraSIP LLC
18.18. Phagenesis
18.19. ProvaMed®
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Dysphagia Management Industry Analysis in the United Kingdom
